A COST-UTILITY ANALYSIS ON THE USE OF TRASTUZUMAB plus ANASTROZOLE COMPARED TO LAPATINIB plus LETROZOLE, LETROZOLE MONOTHERAPY OR ANASTROZOLE MONOTHERAPY IN THE TREATMENT OF HER2+/HORMONE RECEPTOR POSITIVE (HR plus ) METASTATIC BREAST CANCER (MBC) FROM THE PERSPECTIVE OF THE UK NATIONAL HEALTH SERVICE (NHS)

被引：0
|
作者：
McNamara, S. [1 ]
Moore, L. [1 ]
Ray, J. [2 ]
机构：
[1] Roche Prod Ltd, Welwyn Garden City AL7 3AY, Herts, England
[2] F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland
来源：
VALUE IN HEALTH | 2010年 / 13卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A269 / A269
页数：1
相关论文
共 50 条
  • [31] Lapatinib plus Letrozole as First-Line Therapy for HER-2+ Hormone Receptor-Positive Metastatic Breast Cancer (vol 15, pg 122, 2010)
    Schwartzberg, Lee S.
    Franco, Sandra X.
    Florance, Allison
    O'Rourke, Lisa
    Maltzman, Julie
    Johnston, Stephen
    ONCOLOGIST, 2010, 15 (03): : 327 - 327
  • [32] COST-UTILITY MODEL OF TRASTUZUMAB EMTANSINE (T-DM1) IN HER2-POSITIVE, UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC BREAST CANCER PREVIOUSLY TREATED WITH TRASTUZUMAB AND A TAXANE, COMPARED WITH CAPECITABINE PLUS LAPATINIB, TRASTUZUMAB PLUS CAPECITABINE AND CAPECITABINE ALONE IN TURKEY
    Akyol Ersoy, B.
    Erdogan-Ciftci, E.
    Yanik, L.
    Guler, B.
    Ozcan, G.
    Paracha, N.
    VALUE IN HEALTH, 2020, 23 : S441 - S441
  • [33] Impact of palbociclib plus letrozole on health related quality of life (HRQOL) compared with letrozole alone in treatment naive postmenopausal patients with ER+HER2-metastatic breast cancer (MBC): results from PALOMA-2
    Rugo, H.
    Dieras, V.
    Gelmon, K. A.
    Finn, R.
    Slamon, D.
    Miguel, M.
    Neven, P.
    Ettl, J.
    Shparyk, Y.
    Mori, A.
    Lu, D. R.
    Bhattacharyya, H.
    Bartlett, C. H.
    Iyer, S.
    Johnston, S.
    Harbeck, N.
    ANNALS OF ONCOLOGY, 2016, 27
  • [34] Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study
    Kaufman, Bella
    Mackey, John R.
    Clemens, Michael R.
    Bapsy, Poonamalle P.
    Vaid, Ashok
    Wardley, Andrew
    Tjulandin, Sergei
    Jahn, Michaela
    Lehle, Michaela
    Feyereislova, Andrea
    Revil, Cedric
    Jones, Alison
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (33) : 5529 - 5537
  • [35] First-line lapatinib combined with letrozole versus letrozole alone for hormone receptor positive (HR plus ) metastatic breast cancer (MBC): Subgroup analyses of borderline FISH+, IHC 2+, HER2 unknown (UNK), and treatment-naive (TN) populations from EGF30008
    O'Rourke, L.
    Pegram, M.
    Press, M.
    Pippen, J.
    Pivot, X.
    Gomez, H.
    Florance, A.
    Maltzman, J.
    Johnston, S.
    Johnston, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [36] Quality-adjusted survival analysis of first-line treatment of hormone-receptor-positive HER2+ metastatic breast cancer with letrozole alone or in combination with lapatinib
    Sherrill, Beth
    Sherif, Bintu
    Amonkar, Mayur M.
    Maltzman, Julie
    O'Rourke, Lisa
    Johnston, Stephen
    CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 (12) : 2245 - 2252
  • [37] ALTERNATIVE: safety and efficacy of lapatinib (L), trastuzumab (T), or both in combination with an aromatase inhibitor (Al) for the treatment of hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer
    Johnston, S.
    Wroblewski, S.
    Huang, Y.
    Harvey, C.
    Nagi, F.
    Franklin, N.
    Gradishar, W.
    CANCER RESEARCH, 2012, 72
  • [38] PATIENT PREFERENCE-BASED UTILITY WEIGHTS FROM THE FUNCTIONAL ASSESSMENT OF CANCER THERAPY-GENERAL (FACT-G) IN WOMEN WITH HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER RECEIVING LETROZOLE PLUS LAPATINIB OR LETROZOLE ALONE
    Delea, T. E.
    Sofrygin, O.
    Amonkar, M.
    VALUE IN HEALTH, 2010, 13 (03) : A43 - A44
  • [39] Half-dose fulvestrant plus anastrozole as a first-line treatment for hormone receptor-positive metastatic breast cancer: a cost-effectiveness analysis
    Huang, Xiaoting
    Weng, Xiuhua
    Lin, Shen
    Liu, Yiwei
    Luo, Shaohong
    Wang, Hang
    Ming, Wai-kit
    Huang, Pinfang
    BMJ OPEN, 2020, 10 (08):
  • [40] Neratinib plus fulvestrant plus trastzuzumab (N plus F plus T) for hormone receptor-positive (HR+), HER2-negative, HER2-mutant metastatic breast cancer (MBC): Outcomes and biomarker analysis from the SUMMIT trial.
    Jhaveri, Komal L.
    Goldman, Jonathan W.
    Hurvitz, Sara A.
    Guerrero-Zotano, Angel
    Unni, Nisha
    Brufsky, Adam
    Park, Haeseong
    Waisman, James Ross
    Yang, Eddy Shih-Hsin
    Spanggaard, Iben
    Reid, Sonya A.
    Burkard, Mark E.
    Prat, Aleix
    Loi, Sherene
    Crown, John
    Hanker, Ariella
    Ma, Cynthia X.
    Bose, Ron
    Eli, Lisa DeFazio
    Wildiers, Hans
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345